XML 19 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Profit or loss [abstract]    
Sales $ 2,160,052 $ 2,619,682
Cost of sales 1,908,515 566,252
Gross Profit before gain (loss) on change in fair value of biological assets and inventory 251,537 2,053,430
Gain (Loss) on change in fair value of biological assets and inventory (140,088) 1,216,129
Gross Profit 111,449 3,269,559
Operating expenses    
Depreciation and amortization 4,283,731 3,598,323
Consulting and professional fees 2,978,321 7,759,824
Personnel expenses 2,395,583 6,593,527
Share-based payment expenses to social development trust 2,124,615
General and administrative expenses 505,187 3,369,659
Total operating expenses 10,162,822 23,445,948
Operating loss (10,051,373) (20,176,389)
Other income (expenses):    
Finance income 39 886
Finance expense (255,656) (115,324)
Foreign exchange gain (loss), net 148,823 (256,431)
Gain on bargain purchase 12,760,356
Gain on debt settlement 113,037 67,075
Other income 7,055 659
Change in fair value of financial assets measured at FVTPL (264,655) (516,281)
Loss on disposal of assets (4,495)
Write-off of AP, net 2,697,719
Impairment loss (24,665,564)
Total Other income (22,223,697) 11,940,940
Net loss from continuing operations (32,275,070) (8,235,449)
Loss from discontinued operations (3,422,225)
Net loss (32,275,070) (11,657,674)
Translation adjustment (39,412) (1,395,508)
Comprehensive loss $ (32,314,482) $ (13,053,182)
Loss per share from continuing operations — basic (in Dollars per share) $ (7.16) $ (2.75)
Loss per share – basic (in Dollars per share) $ (7.16) $ (3.86)
Weighted average common shares outstanding (in Shares) 4,505,263 2,993,009